Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

More postpartum weight gain with dolutegravir-based ART

Key clinical point: Women with HIV on dolutegravir-based antiretroviral therapy protocols had higher weights through 18 months of the postpartum period than women on efavirenz-based therapy, but similar postpartum weights to women who did not have HIV.

Major finding: Women on a dolutegravir-based regiment weighed an average of 5 kg more post partum than women on an efavirenz-based regiment. (P less than .01).

Study details: The study was a secondary analysis of the Botswanan Tshilo Dikotla study that included 406 women.

Disclosures: The study was supported by the National Institutes of Health. Dr. Jao reported no relevant conflicts of interest.


Jao J et al. CROI 2020, Poster 00772.